SCHEMBL3086752

SCHEMBL3086752

C[C@@H](O)CN(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL907639 1.00
SCHEMBL9188538 1.00
SCHEMBL8389 1.00
Ammonia Solution, Strong SCHEMBL5609160 0.97
Hydrochloric Acid SCHEMBL232631 0.97
SCHEMBL25302485 0.97
Hydrochloric Acid SCHEMBL1577130 0.97
SCHEMBL29034425 0.97
Hydrochloric Acid SCHEMBL3086623 0.97
SCHEMBL25255331 0.97 TSHR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799952-B2 Stereoselective method for the production of (R)-Dimepranol RATIOPHARM GMBH (DE) 2010-09-21 US claimed
US-20090149677-A1 Stereoselective Method for the Production of (R)-Dimepranol RATIOPHARM GMBH (DE) 2009-06-11 US claimed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 US disclosed
US-20260124147-A1 THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS Vima Therapeutics, Inc. (US) 2026-05-07 US disclosed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
US-20250339418-A1 THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS Vima Therapeutics, Inc. (US) 2025-11-06 US disclosed
US-20250268883-A1 THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS Vima Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12290513-B2 Therapeutic methods and compositions for treating movement disorders Vima Therapeutics, Inc. (US) 2025-05-06 US disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-04-03 US disclosed
EP-1737868-A1 STEREOSELECTIVE METHOD FOR THE PRODUCTION OF CLOPIDOGREL ratiopharm GmbH (DE) 2007-01-03 EP disclosed
WO-2005113559-A1 STEREOSELECTIVE METHOD FOR THE PRODUCTION OF CLOPIDOGREL RATIOPHARM GMBH (DE) 2005-12-01 WO disclosed
EP-1589019-A1 Stereoselective process for the preparation of Clopidogrel Ratiopharm GmbH (DE) 2005-10-26 EP disclosed
US-20030045727-A1 Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-03-06 US disclosed
EP-1254885-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS Asahi Kasei Kabushiki Kaisha (JP) 2002-11-06 EP disclosed
US-6143933-A Process for the preparation of optically active methadones in high enantiomeric purity SALFORD ULTRAFINE CHEMICALS & RESEARCH LTD. (GB) 2000-11-07 US disclosed
EP-0914464-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE METHADONES IN HIGH ENANTIOMERIC PURITY SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED (GB) 1999-05-12 EP disclosed
WO-1997045551-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE METHADONES IN HIGH ENANTIOMERIC PURITY SALFORD ULTRAFINE CHEMICALS & RESEARCH LIMITED (GB) 1997-12-04 WO disclosed
EP-0641564-A1 OPTICALLY ACTIVE CONDENSED PYRAZOLE COMPOUND FOR USE IN TREATING THROMBOCYTOPENIA AND ERYTHROPENIA YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-03-08 EP disclosed